Search Results
Your search for ,USE matches 11256 pages
Showing 7051 - 7100Expert Point of View: Virginia Kaklamani, MD
How can the results of this trial be applied to clinical practice? Press conference moderator, Virginia Kaklamani, MD, of the University of Texas Health Science Center in San Antonio, said: “The landscape has changed. Now we treat postmenopausal hormone receptor–positive, HER2-negative metastatic...
Fulvestrant Plus Everolimus: New Second-Line Option for Postmenopausal Metastatic Breast Cancer
The addition of everolimus (Afinitor) to fulvestrant (Faslodex) doubled progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer resistant to aromatase inhibitor therapy compared with fulvestrant plus placebo, according to the...
FDA Permits Marketing of New Tissue Expander for Women Undergoing Breast Reconstruction Following Mastectomy
On December 21, the U.S. Food and Drug Administration (FDA) allowed marketing of a new tissue-expander system for soft-tissue expansion in two-stage breast reconstruction following mastectomy and in the treatment of underdeveloped breasts and soft-tissue deformities. A patient uses a dose...
Expert Point of View: Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, MS, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Center in Ohio, commented on vadastuximab talirine in newly diagnosed acute myeloid leukemia (AML). He noted that the drug is similar to gemtuzumab ozogamicin, another antibody-drug conjugate that...
Expert Point of View: Lawrence Kaplan, MD
“This study is important because R-CHOP [rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone] has been the standard of care for many years. CHOP, the chemotherapy backbone, has withstood challenges from more aggressive regimens in the past. The excellent clinical outcomes observed ...
Weighing the Benefits and Risks of Medical Marijuana
Despite the fact that 28 states and the District of Columbia have enacted laws to permit the use of cannabis and cannabinoid-based drugs to treat medical conditions, including cancer and symptoms from its treatment, federal law prohibits physicians from prescribing marijuana to their patients,...
Dose-Adjusted EPOCH-R No Better Than R-CHOP in Diffuse Large B-Cell Lymphoma
Long-awaited results of the Cancer and Leukemia Group B (CALGB)/Alliance 50303 trial were a disappointment to many hematologists/oncologists at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition. The study failed to show that dose-adjusted EPOCH-R (etoposide,...
Accelerating Progress in the Treatment of Glioblastoma Multiforme
W.K. Alfred Yung, MD, has wanted a career in medicine since he was a high-school student and has spent nearly 4 decades fulfilling that dream, specifically in the research and treatment of one of the deadliest cancers, malignant brain tumor, especially glioblastoma multiforme, the most common...
Expert Point of View: Brad S. Kahl, MD
Speaking about the GALLIUM study in the ASH News Daily, Brad S. Kahl, MD, of Washington University School of Medicine, St. Louis, commented, “It is a potentially practice-changing study that clearly shows an 8% absolute improvement in progression-free survival at 2 years for the patients getting...
Updated ASTRO Guideline Expands Pool of Suitable Candidates for Accelerated Partial-Breast Irradiation
On November 17, 2016, the American Society for Radiation Oncology (ASTRO) issued an updated clinical practice statement for accelerated partial-breast irradiation for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients may benefit from...
Confirmation or Transformation? The Case of Palbociclib in Hormone Receptor–Positive Metastatic Breast Cancer
Women with hormone receptor–positive metastatic breast cancer are witnessing an unprecedented time of success in the battle against their disease. Just in the past 12 months, a number of prospective, randomized, phase III studies were reported, with positive results indicating the value of...
Single Autotransplant Not Enhanced by Additional Interventions in Multiple Myeloma
Additional interventions following upfront autologous stem cell transplant in multiple myeloma did not further improve progression-free or overall survival over transplant alone in a multicenter study presented as a late-breaking abstract at the 2016 American Society of Hematology (ASH) Annual...
Lawrence N. Shulman, MD, FACP, Named Chair of American College of Surgeons’ Commission on Cancer
Lawrence N. Shulman, MD, FACP, Professor of Medicine in the Perelman School of Medicine and Deputy Director for Clinical Services of the Abramson Cancer Center at the University of Pennsylvania, has been named the new Chair of the Commission on Cancer of the American College of Surgeons. The...
Achieving Complete Response Is Key to Improving Survival in Older Patients With AML
The importance of achieving complete response after intensive therapy in older adults with acute myeloid leukemia (AML) was confirmed in a follow-up analysis of the E2906 North American Intergroup trial.1 Patients in complete response had superior survival in this landmark analysis. This finding...
A Gleason 6 Tumor: Is It Cancer, and Should It Be Treated?
The diagnosis and treatment of prostate cancer have long been a source of controversy among the oncology community, the political sector, and patient advocacy groups. Most notably, the decision to biopsy a man’s prostate gland rests largely on his prostate-specific antigen (PSA) test numbers, the...
Expert Point of View: Michael Gnant, MD
Michael Gnant, MD, Professor of Surgery at the Medical University of Vienna in Austria and President of the Austrian Breast & Colorectal Cancer Study Group, was the invited discussant of the three studies of extended endocrine therapy. “The trials did not reach the necessary statistical levels ...
Benefit of Extended Adjuvant Endocrine Therapy Not Upheld in Multiple Studies Reported in San Antonio
Extended endocrine therapy with an aromatase inhibitor did not improve disease-free survival in patients with hormone receptor–positive breast cancer enrolled in three studies presented at the 2016 San Antonio Breast Cancer Symposium. The results stand in contrast to the phase III National Cancer...
Atezolizumab Shows Activity in First-Line Treatment of Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma
In a phase II trial reported in The Lancet, Balar et al found that first-line atezolizumab (Tecentriq) produced durable responses in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. In the study, 119 patients from 47 sites in North America and Europe who were ...
ESMO Asia 2016: Study Validates Set of Six Adaptable Prognosis Prediction Models for Patients With Cancer in Palliative Care Settings
A routine blood test may predict how long patients with cancer in palliative care will survive, researchers reported at the ESMO Asia 2016 Congress in Singapore. “Cancer patients in palliative care want honest and accurate prognostic information but this information needs to be shared...
FDA Approves Rucaparib and Companion Genetic Test in Advanced Deleterious BRCA-Mutated Ovarian Cancer
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to rucaparib (Rubraca) to treat women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved...
ESMO Asia 2016: First Data Presented on Rare Sarcomas in Asian Patients
The first data on rare sarcomas in Asian patients were presented in three studies at the ESMO Asia 2016 Congress in Singapore. Just half of patients with advanced angiosarcoma received chemotherapy, although it improved overall survival. CIC-rearranged sarcomas were associated with a much worse...
T-Cell Transfer Therapy Targets Mutant KRAS in Metastatic Colorectal Cancer
In a case report in The New England Journal of Medicine, Tran et al at the National Cancer Institute describe response to adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes containing T cells targeting personalized cancer neoepitopes in a patient with lung metastases from...
ESMO Asia 2016: Almost 20% of Swedish Breast Cancer Patients Fail to Complete Prescribed Endocrine Therapy
Around 20% of patients with breast cancer in Sweden do not complete endocrine therapy, according to research that will be reported at the ESMO Asia 2016 Congress (Abstract 62O_PR), to be held December 16–19 in Singapore.The study in over 5,500 women found that younger patients and those who...
Effectiveness of Electroacupuncture for Sleep Disturbances in Patients With Breast Cancer and Hot Flashes
Studies suggest that approximately 30% to 40% of women with breast cancer report persistent hot flashes. Nocturnal hot flashes are among the most problematic because they can contribute to poor sleep. A new study published by Garland et al in Menopause shows that electroacupuncture may be effective ...
ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers. Recommendations were developed by an expert panel using a ...
SABCS 2016: Aromatase Inhibitors Were Associated With Reduced Endothelial Function in Postmenopausal Breast Cancer Patients
Postmenopausal women with breast cancer who took aromatase inhibitors demonstrated endothelial dysfunction, a predictor of cardiovascular disease, according to study results presented at the 2016 San Antonio Breast Cancer Symposium, held December 6 to 10 (Abstract s5-07). Aromatase inhibitors are...
Intensity-Modulated vs Three-Dimensional Conformal External-Beam Radiation Therapy in Locally Advanced Non–Small Cell Lung Cancer
In a secondary analysis from the NRG Oncology RTOG 0617 trial reported in the Journal of Clinical Oncology, Stephen G. Chun, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and colleagues found that use of intensity-modulated vs three-dimensional...
Expect Questions About Cardiovascular Risk Factors Among Cancer Survivors
Reports of rare, but in some cases fatal, cardiac complications when the checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) are used in combination should be taken seriously but should not scare patients away from potentially life-saving drugs, according to Javid J. Moslehi, MD. Dr....
SABCS 2016: Women Experiencing Menopausal Symptoms Less Likely to Adhere to Medication in IBIS-1 Trial
Among women enrolled in the International Breast Cancer Intervention Study I (IBIS-I), those who had certain symptoms of menopause—nausea/vomiting and headaches—were significantly less likely to be adherent to the assigned medication 4.5 years after starting the treatment, according to...
SABCS 2016: Neoadjuvant Abemaciclib Treatment May Benefit Patients With Early-Stage Hormone Receptor–Positive, HER2-Negative Breast Cancer
Presurgical treatment with the investigational therapeutic abemaciclib, either alone or in combination with the aromatase inhibitor anastrozole, reduced levels of Ki67, a marker of cell proliferation, in hormone receptor–positive, HER2-negative breast cancer cells, compared with anastrozole...
Valerian
Scientific Names: Valeriana officinalis, Valeriana radix Common Names: Garden valerian, Indian valerian, Pacific valerian, garden heliotrope Overview A perennial flowering plant prevalent in Europe, Asia, and North America, valerian has a long medicinal history as a relaxant. Its potential as a...
Profound Answers to Simple Questions
A few years ago, I had the good fortune to join a research team that intended to create a device to help dying children express their wants and needs despite communication challenges. The brain tumor team at SickKids [also known as The Hospital for Sick Children] had cared for several children...
Seven MD Anderson Faculty Elected Fellows of the American Association for the Advancement of Science
In recognition of wide-ranging contributions to the fields of cancer prevention; patient care; and basic, translational, and clinical research, seven faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of...
Using Art to Humanize Medicine
Among the most widely attended sessions at the 2016 Palliative Care in Oncology Symposium in September was the keynote lecture, “Wit, Hex, Vin, Life, Death: Using Wit as a Teaching Tool,” given by Margaret Edson, author of the Pulitzer Prize–winning play Wit. Wit tells the story of an accomplished ...
Approval of Dinutuximab for High-Risk Neuroblastoma: Lessons Learned in Expediting the Development of Pediatric Cancer Drugs
On March 10, 2015, the U.S. Food and Drug Administration (FDA) granted regular approval to dinutuximab (formerly known as chimeric 14.18 antibody; Unituxin) for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid...
Faculty Development in Oncology: Advancing the Field by Optimizing Opportunities for Educators to Learn and Grow
In 2015, Janet Riddle, MD, and her colleagues published an article1 outlining 12 key themes for delineating how fellowship programs in medical education should be developed (See “12 Tips for Developing Successful Fellowship Programs for Medical Educators,” below.) The ASCO Post talked with Dr....
Precautions in Cancer Rehabilitation Services: Imperative or Impediment in Patient Care?
GUEST EDITOR Physiatry in Oncology explores the benefits of cancer rehabilitation in oncology practice to screen survivors for physical and cognitive impairments along the care continuum to minimize survivors’ disability and maximize their quality of life. The column is guest edited by Sean Smith, ...
William Sellers, MD, Appointed to Faculty at Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School
William Sellers, MD, a widely respected cancer researcher with extensive experience in cancer genomics and therapeutic discovery, is returning to the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard, Dana-Farber Cancer Institute, and Harvard Medical School (HMS) as a...
Friends of Cancer Research Rethinks Traditional Clinical Trials
Ellen V. Sigal, PhD, Chair and Founder of Friends of Cancer Research (Friends) began the annual meeting with a conversation with Douglas R. Lowy, MD, National Cancer Institute (NCI) Acting Director, and Robert M. Califf, MD, U.S. Food and Drug Administration (FDA) Commissioner. “Cancer research is ...
ASCO Releases Criteria for High-Quality Clinical Pathways in Oncology
ASCO recently released its Criteria for High-Quality Clinical Pathways in Oncology, a set of 15 interrelated criteria that provide an overarching framework for assessing pathway programs in the United States. ASCO developed the criteria to guide stakeholders in assessing the quality, utility, and...
NCCN Launches Campaign to Eradicate Fatal Vincristine Errors
It is uniformly fatal and impossible to undo. When the chemotherapy drug vincristine is placed in a syringe and injected intrathecally—into the spinal fluid—the patient always dies. And despite safety guidelines and labels, deaths continue to occur. Now the National Comprehensive Cancer Network®...
Sodium Thiosulfate Seems to Protect Against Cisplatin-Related Hearing Loss in Children With Cancer
The antioxidant sodium thiosulfate provided protection against cisplatin-related hearing loss in children with cancer, according to a phase III trial reported by Freyer et al in The Lancet Oncology. The open-label trial included 104 assessable patients (aged 1 to 18 years) from 38 Children’s ...
ASH Launches Digital, Open-Access Journal Blood Advances at 2016 Annual Meeting
Blood has covered experimental and clinical hematologic research as the flagship journal of the American Society of Hematology (ASH). Launched officially on November 29, 2016, the open-access online journal Blood Advances will fill a niche that complements and expands on topics covered in Blood...
What’s New in Antiemesis Therapy
The optimal use of new antiemetics was the subject of a presentation at the 14th Annual School of Breast Oncology, Emory University, Atlanta, by Frankie Ann Holmes, MD, Associate Director of Breast Oncology Research at Texas Oncology, Houston. “The science of nausea and vomiting is so compelling,...
Treatment of Early HER2-Positive Breast Cancer: One Size Does Not Fit All
Despite the routine use of HER2 blockade in early HER2-positive breast cancer, clinicians can always benefit from a refresher on key treatment considerations. Clinical pearls and controversial issues were the topic of a presentation at the 14th Annual School of Breast Oncology at Emory University, ...
The FDA Ensures Quality and Safety of Generic Drugs in the United States
The U.S. Food and Drug Administration’s (FDA) generic drug program has substantially increased the availability of affordable, high-quality drugs in the United States. It is arguably the only really effective health-care cost–containment program. The more than 10,000 generic drugs currently...
David Tuveson, MD, PhD, Named Director of the Cold Spring Harbor Laboratory Cancer Center
David Tuveson, MD, PhD, will succeed Bruce Stillman, AO, FAA, FRS, as Director of the Cold Spring Harbor Laboratory Cancer Center. Dr. Tuveson is the Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory, the Head of the Lustgarten Foundation Pancreatic Cancer Research...
NCCN Imaging Appropriate Use Criteria Published for 15 Additional Guidelines
The National Comprehensive Cancer Network® (NCCN®), a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria, continues to build its library of these standards and has published NCCN Imaging Appropriate Use Criteria™ for an additional 15 ...
Concerns About Safety of Generic Oncology Drugs Made in Developing Countries
In an article in The Lancet Oncology, Y. Tony Yang, ScD, of George Mason University, Charles L. Bennett, MD, PhD, MPP, of the University of South Carolina and colleagues from the United States, Europe, and Japan examined clinical, policy, safety, and regulatory considerations for generic oncology...
SABCS 2016: Adding Everolimus to Fulvestrant Improved Outcomes for Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer
Progression-free survival was more than doubled for patients with metastatic hormone receptor–positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy by adding everolimus (Afinitor) to treatment with the endocrine therapeutic fulvestrant (Faslodex), according to data...
